Felzartamab is under clinical development by MorphoSys and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Felzartamab’s likelihood of approval (LoA) and phase transition for Membranous Glomerulonephritis took place on 14 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Felzartamab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Felzartamab overview

Felzartamab is under development for the treatment of late antibody-mediated renal allograft rejection, IgA nephropathy (IgAN), membranous nephropathy(anti-PLA2R antibody-positive membranous nephropathy), refractory/relapsed multiple myeloma and systemic lupus erythematosus. The drug candidate is administered as an intravenous infusion. It is a fully human monoclonal antibody (mAb) directed against CD38, which is one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells.

It was also under development for the treatment of non-small lung cancer.

MorphoSys overview

MorphoSys is commercial-stage biopharmaceutical company that develop monoclonal antibodies for therapeutic and research applications, with focused on the treatment of cancer and autoimmune diseases. The company’s product pipeline includes tafasitamab, pelabresib, cpi-0209, gantenerumab, otilimab, ianalumab, abelacimab, felzartamab, setrusumab, NOV-8, NOV-14 and MOR210. Its Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. The company provides clinical trials for cancer and inflammatory disorders. MorphoSys also conducts research and development activities with pharmaceutical and biotechnology companies. The company owns a regional licensing agreement to develop and commercialize products. It operates in the US. MorphoSys is headquartered in Planegg, Bayern, Germany.

Quick View Felzartamab LOA Data

Report Segments
  • Innovator
Drug Name
  • Felzartamab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.